Company
Sinocare
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
0
510(k), De Novo and PMA
Device trials
8
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Sinocare, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Sinocare.
Latest FDA decisions
No 510(k), De Novo or PMA decisions under this name since 2015.
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Real-time CGM in Perioperative Glycemic ManagementPivotal-lookingNot yet recruiting
NCT07932678 · 120 participants (planned) · Start Nov 2, 2026 · Primary completion Apr 30, 2027
Device: Real-time continuous glucose monitoring(rtCGM); Point-of-care blood glucose testing (POCT) · For: Stress Hyperglycemia; Perioperative Hyperglycemia
- Effect of CGM on Glucose Control in Non-insulin-treated Patients With Type 2 Diabetes MellitusPivotal-lookingActive, not recruiting
NCT06587438 · 160 participants · Start Jan 17, 2025 · Primary completion Mar 14, 2026
Device: Sinocare iCan I3 CGM; Sinocare jinzhi+Blood glucose meter · For: Diabetes Mellitus
Sites: Beijing, China; Chongqing, China; Shunde, China · 6 sites in all
- To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days PeriodEnrolling by invitation
NCT06904846 · 70 participants (planned) · Start Apr 23, 2025 · Primary completion Apr 30, 2026
Device: iCan o3 CGM Continuous Glucose Monitoring System · For: Diabetes Mellitus; Continuous Glucose Monitoring System
Sites: Antwerp, Belgium
5 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.